Percutaneous Coronary Intervention as a Bridge Therapy for Aortic Dissection Related Bilateral Coronary Malperfusion:

Kuowei Chung1, Poyen Huang1, Kunkuang Lee2

  • 1Division of Cardiology, Department of Internal Medicine, Chi-Mei Medical Center, Liouying Tainan, Taiwan. arther12345a@gmail.com.

Insights

Percutaneous coronary intervention can be an effective bridge therapy for managing coronary artery issues arising from aortic dissection. This approach offers a promising solution for patients experiencing myocardial infarction due to aortic dissection.

Area of Science:

  • Cardiology
  • Vascular Surgery
  • Cardiovascular Imaging

Background:

  • Aortic dissection involving coronary arteries presents significant treatment challenges.
  • Coronary malperfusion is a critical complication of aortic dissection.

Observation:

  • A 57-year-old woman presented with chest pain and ST-elevation myocardial infarction.
  • Initial percutaneous coronary intervention for myocardial infarction led to the incidental diagnosis of aortic dissection.
  • The patient subsequently underwent successful central repair for aortic dissection.

Findings:

  • Percutaneous coronary intervention (PCI) was utilized as a temporary measure before definitive surgical repair.
  • This PCI strategy effectively addressed the coronary malperfusion secondary to aortic dissection.
  • The patient achieved a satisfactory clinical outcome following the combined treatment approach.

Implications:

  • Percutaneous coronary intervention may serve as a valuable bridge therapy in cases of aortic dissection-related coronary malperfusion.
  • This case highlights the importance of considering aortic pathology in patients with myocardial infarction.
  • The findings suggest a potential pathway for improving outcomes in complex cardiovascular emergencies.

Related Concept Videos

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
20
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
16
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
19
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
13